1. An Entirely Subcutaneous Implantable Cardioverter-Defibrillator
- Author
-
David Wright, Riccardo Cappato, Stefan G. Spitzer, Ian Crozier, Alexander H. Maass, Pascal F.H.M. van Dessel, Gust H. Bardy, Robert E. Park, Warren Smith, Ardashev Av, Andrew A. Grace, Isabelle C. Van Gelder, Derek T. Connelly, Francis Murgatroyd, Pierpaolo Lupo, Johannes Sperzel, Dominic A.M.J. Theuns, Lucas V.A. Boersma, A. Oduro, Joerg Neuzner, Craig S. Barr, Reinoud E. Knops, Luc Jordaens, Iain Melton, Margaret Hood, Simon P. Fynn, Arthur A.M. Wilde, ACS - Amsterdam Cardiovascular Sciences, Cardiology, CCA -Cancer Center Amsterdam, APH - Amsterdam Public Health, General Practice, Faculteit Medische Wetenschappen/UMCG, and Cardiovascular Centre (CVC)
- Subjects
Adult ,Male ,medicine.medical_specialty ,Heart Diseases ,Defibrillation ,medicine.medical_treatment ,Pilot Projects ,CHILDREN ,THERAPY ,Sudden death ,PERMANENT PACEMAKER LEADS ,Electrocardiography ,Young Adult ,Internal medicine ,MANAGEMENT ,medicine ,Humans ,FAILURE ,Aged ,Aged, 80 and over ,COMPLICATIONS ,medicine.diagnostic_test ,business.industry ,SURGICAL REVISION ,Stroke Volume ,Equipment Design ,General Medicine ,Stroke volume ,Middle Aged ,Implantable cardioverter-defibrillator ,medicine.disease ,Defibrillators, Implantable ,Electrodes, Implanted ,Surgery ,CONGENITAL HEART-DISEASE ,Clinical trial ,Parasternal line ,Ventricular fibrillation ,Cardiology ,Female ,FOLLOW-UP ,business ,FIDELIS - Abstract
BACKGROUNDImplantable cardioverter-defibrillators (ICDs) prevent sudden death from cardiac causes in selected patients but require the use of transvenous lead systems. To eliminate the need for venous access, we designed and tested an entirely subcutaneous ICD system.METHODSFirst, we conducted two shortterm clinical trials to identify a suitable device configuration and assess energy requirements. We evaluated four subcutaneous ICD configurations in 78 patients who were candidates for ICD implantation and subsequently tested the best configuration in 49 additional patients to determine the subcutaneous defibrillation thresh old in comparison with that of the standard transvenous ICD. Then we evaluated the long-term use of subcutaneous ICDs in a pilot study, involving 6 patients, which was followed by a trial involving 55 patients.RESULTSThe best device configuration consisted of a parasternal electrode and a left lateral thoracic pulse generator. This configuration was as effective as a transvenous ICD for terminating induced ventricular fibrillation, albeit with a significantly higher mean (+/- SD) energy requirement (36.6 +/- 19.8 J vs. 11.1 +/- 8.5 J). Among patients who received a permanent subcutaneous ICD, ventricular fibrillation was successfully detected in 100% of 137 induced episodes. Induced ventricular fibrillation was converted twice in 58 of 59 patients (98%) with the delivery of 65-J shocks in two consecutive tests. Clinically significant adverse events included two pocket infections and four lead revisions. After a mean of 10 +/- 1 months, the device had successfully detected and treated all 12 episodes of spontaneous, sustained ventricular tachyarrhythmia.CONCLUSIONSIn small, nonrandomized studies, an entirely subcutaneous ICD consistently detected and converted ventricular fibrillation induced during electrophysiological testing. The device also successfully detected and treated all 12 episodes of spontaneous, sustained ventricular tachyarrhythmia. (ClinicalTrials.gov numbers, NCT00399217 and NCT00853645.)
- Published
- 2010